OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial
Status:
Completed
Trial end date:
2017-11-28
Target enrollment:
Participant gender:
Summary
High on-treatment platelet reactivity (HOPR) is associated with increased risk of
cardiovascular events in patients undergoing percutaneous coronary intervention (PCI). We
sought to investigate the efficacy and safety of 1-month intensified antiplatelet therapies
in post-PCI patients with HOPR.
Phase:
Phase 4
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University